AI reads tumor slides: can computer scores predict who will do well?

NCT ID NCT07706842

Not yet recruiting Knowledge-focused Sponsor: Ataraxis AI, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study enrolls 1,000 adults with solid tumors, including breast cancer, who receive an AI-based pathology test as part of their routine care. Researchers will link the AI test results with short- and long-term health outcomes to see how well the scores predict prognosis and treatment response. The goal is to evaluate the real-world performance and usefulness of this digital pathology tool across diverse patient populations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ataraxis AI digital pathology test
What this could lead to: If successful, this registry could show that AI-based pathology scores accurately predict patient outcomes, helping doctors tailor treatments for solid tumors.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may vary across different patient groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SOLID TUMOR MALIGNANCY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.